Recent Company News

• 09:29 AM ET Aug 24, 2026
  

  Follow-up: Capricor Therapeutics announces extension of PDUFA date for deramiocel BLA, until 22-Nov ($6.29, 0.00)

• 07:28 AM ET Aug 24, 2026
  

  REGENXBIO announces FDA has placed clinical hold on RGX-121 for MPS II (7:05ET) ($10.72, 0.00)

• 05:07 PM ET Aug 22, 2026
  

  FDA grants orphan drug designation to pirtobrutinib for ITP ($1255.40, 0.00)

• 11:03 PM ET Aug 05, 2026
  

  Nippon Shinyaku reports Q1 net income attributable ¥10.11B vs FactSet ¥6.80B [4 est, ¥4.30-8.18B] (¥3522.0000, +49)

• 10:42 AM ET Aug 05, 2026
  

  Epilepsia Open publishes results of post hoc data analysis of FINTEPLA (fenfluramine) in patients with Lennox-Gastaut syndrome (€230.10, +6.80)

• 08:50 AM ET Jul 30, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:24 PM ET Jul 30, 2026
  

  Nippon Shinyaku downgraded to neutral from buy at Mizuho Securities

• 09:45 AM ET Jul 30, 2026
  

  Nippon Shinyaku exercises option rights for tadekinig alfa in the US (¥3495.0000, 0)

• 09:34 AM ET Jul 30, 2026
  

  Capricor Therapeutics provides update on FDA advisory committee meeting for Deramiocel ($3.38, -3.19)